Blueprint Medicines Co. (NASDAQ:BPMC) Insider L. Becker Hewes Sells 4,922 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMCGet Free Report) insider L. Becker Hewes sold 4,922 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $106.43, for a total value of $523,848.46. Following the completion of the transaction, the insider now directly owns 31,938 shares of the company’s stock, valued at $3,399,161.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

L. Becker Hewes also recently made the following trade(s):

  • On Friday, May 31st, L. Becker Hewes sold 34,108 shares of Blueprint Medicines stock. The shares were sold at an average price of $105.91, for a total transaction of $3,612,378.28.
  • On Thursday, March 7th, L. Becker Hewes sold 3,097 shares of Blueprint Medicines stock. The shares were sold at an average price of $90.69, for a total transaction of $280,866.93.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC opened at $101.89 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76. Blueprint Medicines Co. has a one year low of $43.89 and a one year high of $111.02. The firm has a market capitalization of $6.38 billion, a P/E ratio of -21.18 and a beta of 0.70. The company’s fifty day moving average is $97.99 and its two-hundred day moving average is $88.51.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.64) by $0.32. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The company had revenue of $96.12 million for the quarter, compared to analyst estimates of $82.58 million. Analysts forecast that Blueprint Medicines Co. will post -5.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on BPMC. HC Wainwright boosted their target price on Blueprint Medicines from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Leerink Partnrs upgraded Blueprint Medicines from an “underperform” rating to a “market perform” rating in a research note on Monday, May 6th. Wedbush restated an “outperform” rating and set a $110.00 target price on shares of Blueprint Medicines in a research report on Friday, April 26th. SVB Leerink upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and upped their price target for the company from $50.00 to $97.00 in a research report on Monday, May 6th. Finally, StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $103.94.

View Our Latest Stock Report on BPMC

Hedge Funds Weigh In On Blueprint Medicines

Several hedge funds have recently bought and sold shares of the company. Covestor Ltd boosted its position in Blueprint Medicines by 9,700.0% during the first quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 291 shares in the last quarter. Cutler Group LLC CA grew its stake in Blueprint Medicines by 1,685.7% in the 3rd quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 944 shares during the last quarter. Headlands Technologies LLC increased its holdings in Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 342 shares in the last quarter. Compass Wealth Management LLC acquired a new position in Blueprint Medicines during the fourth quarter worth about $69,000. Finally, Natixis purchased a new stake in shares of Blueprint Medicines in the first quarter valued at about $73,000.

Blueprint Medicines Company Profile

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

Further Reading

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.